RxDoctor Payments Data

Michael Tolle, MD

Family Medicine · Dallas, TXNPI 1568486389

Payments from drug & device makers

$4,932in general payments, 2019–2025

Across 273 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$716
  • Pfizer$513
  • AstraZeneca$504
  • Astellas Pharma US Inc$473
  • GSK$383
  • AbbVie$381
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,85798%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,932 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$141,298
Medicare patients
444
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin77$93,551
OzempicSemaglutide50$50,811
RybelsusSemaglutide29$49,672
TriumeqAbacavir/Dolutegravir/Lamivudi12$44,970
EliquisApixaban52$44,221
XareltoRivaroxaban31$36,611
JanuviaSitagliptin Phosphate19$28,530
TrulicityDulaglutide25$24,454
MounjaroTirzepatide11$23,420
FarxigaDapagliflozin Propanediol16$20,484
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$19,830
JanumetSitagliptin Phos/Metformin Hcl13$16,326
VascepaIcosapent Ethyl30$16,066
Repatha SureclickEvolocumab19$12,985
SymbicortBudesonide/Formoterol Fumarate49$11,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$377$100,48479 claims
Boehringer IngelheimJardiance$58$93,55177 claims
Lilly USA, LLCTrulicity, Mounjaro$716$47,87436 claims
Viiv Healthcare CompanyTriumeq$25$44,97012 claims
MerckJanuvia, Janumet$89$44,85632 claims
PfizerEliquis$513$44,22152 claims
AstraZenecaFarxiga, Symbicort$504$31,81665 claims
GSKTrelegy Ellipta$383$19,83031 claims
AbbVieSynthroid$381$7,23777 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →